← Back to Search

Brain Imaging for Post-Heart Attack Inflammation

Phase 1
Waitlist Available
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Admission to UAB Hospital for ST-elevation acute myocardial infarction (AMI) and treatment with percutaneous coronary intervention (PCI) OR Undergoing elective percutaneous coronary intervention (PCI)
21 years of age or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will test if an investigational drug can show brain inflammation after a heart attack. It may help develop new treatments to protect the brain.

Who is the study for?
This trial is for adults over 21 who've had a recent heart attack treated with PCI or are undergoing elective PCI. They must speak English, have at least an 8th-grade education, and be genetically predisposed to brain inflammation after a heart attack. People can't join if they're pregnant, breastfeeding, have serious health issues that could affect participation, history of severe head injury, major depression or dementia.Check my eligibility
What is being tested?
The study tests whether PET/MRI scans using the investigational drug [18F]DPA-714 can detect brain inflammation following a heart attack. This research aims to understand how heart disease affects the brain and may lead to new protective treatments.See study design
What are the potential side effects?
[18F]DPA-714-PET/MRI side effects aren't detailed here but generally include potential reactions from the imaging agent like mild irritation or allergic response and discomfort from lying still during scanning.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am admitted to UAB Hospital for a severe heart attack and treated with PCI, or I am undergoing elective PCI.
Select...
I am 21 years old or older.
Select...
I speak English and have completed at least 8th grade.
Select...
My genetic test shows I have a specific marker (rs6971) for TSPO ligands.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
TPSO-PET measurement of neuroinflammation after acute myocardial infarction

Trial Design

2Treatment groups
Experimental Treatment
Group I: undergoing elective percutaneous coronary interventionExperimental Treatment1 Intervention
Group II: Recent Myocardial InfarctionExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,564 Previous Clinical Trials
2,268,263 Total Patients Enrolled

Media Library

[18F]DPA-714-PET/MRI Clinical Trial Eligibility Overview. Trial Name: NCT03968445 — Phase 1
Heart Attack Research Study Groups: undergoing elective percutaneous coronary intervention, Recent Myocardial Infarction
Heart Attack Clinical Trial 2023: [18F]DPA-714-PET/MRI Highlights & Side Effects. Trial Name: NCT03968445 — Phase 1
[18F]DPA-714-PET/MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT03968445 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently enrolled in this research initiative?

"Appropriately, clinicaltrials.gov states that this experiment is currently searching for volunteers; it was initially posted on October 17th 2019 and last updated on August 25th 2022. The research requires 20 participants to be sourced from 1 location."

Answered by AI

What potential risks are associated with the use of [18F]DPA-714-PET/MRI?

"[18F]DPA-714-PET/MRI's safety rating is a 1 due to the fact that this Phase 1 trial has minimal data corroborating its efficacy and security."

Answered by AI

Is the enrollment phase of this trial ongoing?

"According to clinicaltrials.gov, this investigation is actively recruiting participants as of August 25th 2022. The trial was first published on October 17th 2019."

Answered by AI
~1 spots leftby Oct 2024